Peter Harmel1, Frieder Schlunk2, Lutz Harms2. 1. Department for Neurology, Charite-University Medicine Berlin, Berlin, Germany/Center for Stroke Research Berlin, Charite-University Medicine Berlin, Berlin, Germany. 2. Department for Neurology, Charite-University Medicine Berlin, Berlin, Germany.
Abstract
BACKGROUND: Rebound phenomena after discontinuation of different treatments for relapsing-remitting multiple sclerosis (RRMS) have previously been described. Systematic database research in PubMed did not show any report with relapse directly associated with dimethyl fumarate (DMF) cessation. CASE PRESENTATION: Here, we report on a 38-year-old Caucasian male patient suffering from a relatively mild course of RRMS who developed a fulminant clinical rebound 2 months after discontinuation of DMF therapy. Radiological alterations presented impressively with primarily spinal involvement. The patient received intensive care and multiple immunomodulating therapies. CONCLUSION: We report on this case to raise neurologist's awareness of complications of basic therapy discontinuation in RRMS.
BACKGROUND: Rebound phenomena after discontinuation of different treatments for relapsing-remitting multiple sclerosis (RRMS) have previously been described. Systematic database research in PubMed did not show any report with relapse directly associated with dimethyl fumarate (DMF) cessation. CASE PRESENTATION: Here, we report on a 38-year-old Caucasian male patient suffering from a relatively mild course of RRMS who developed a fulminant clinical rebound 2 months after discontinuation of DMF therapy. Radiological alterations presented impressively with primarily spinal involvement. The patient received intensive care and multiple immunomodulating therapies. CONCLUSION: We report on this case to raise neurologist's awareness of complications of basic therapy discontinuation in RRMS.
Authors: S K Vainio; A M Dickens; M Matilainen; F R López-Picón; R Aarnio; O Eskola; O Solin; D C Anthony; J O Rinne; L Airas; M Haaparanta-Solin Journal: EJNMMI Res Date: 2022-02-02 Impact factor: 3.138